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C ardiovascular disease (CVD) remains a leading cause of death in patients with type 2 diabetes (T2D). In addition to glycemic control, a major focus of diabetes treatment involves cardiovascular (CV) risk reduction. In 2008, the US Food and Drug Administration (FDA) instituted a new requirement that new drugs developed and studied for the treatment of T2D must undergo CV safety testing. Since the advent of this new policy, canagliflozin, empagliflozin, liraglutide and semaglutide have demonstrated superior CV event reduction -via a composite of reduction in CV death, nonfatal myocardial infarction (MI), and nonfatal stroke -compared with placebo in patients with T2D and existing CVD, or at high risk of CVD. Multiple studies are underway to evaluate the CV outcomes of other antihyperglycemic agents. In a time when there are numerous drugs in the T2D armamentarium, positive CV outcomes data influence drug selection and aids practitioners in making more individualised therapeutic recommendations for their patients.
(empagliflozin and canagliflozin) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) (liraglutide and semaglutide) are the two major antihyperglycaemic classes to have demonstrated these positive CV findings to date (see Table 1 ).
Empagliflozin was the first of these four antihyperglycaemic agents to demonstrate positive CV outcomes in the Empagliflozin, Cardiovascular
Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial. 9 The EMPA-REG OUTCOME trial included 7,020 patients with T2D and established CVD. At baseline, patients had a mean age of 63 years, glycosylated haemoglobin (A1C) of 8.1%, and more than half of patients had been diagnosed with T2D for more than 10 years. Approximately 75% of patients had coronary artery disease (CAD) and nearly 50% had a history of MI. Patients were randomised to receive empagliflozin 10 mg or 25 m g or placebo once daily. The primary composite major adverse cardiovascular event (MACE) included CV death, nonfatal MI, or nonfatal stroke. The study resulted in significant findings between the pooled empagliflozin-(10 mg and 25 mg) and the placebo-treated patients. The primary CV composite outcome occurred in 10.5% and 12.1% of the empagliflozin-and placebo-treated patients, respectively, over a median of 3.1 years (p=0.04). This results in a number needed to treat (NNT) of 65 patients with T2D and CVD over 3 years to prevent one additional major CV event. There was no difference between the rates of MI or stroke between groups. However, patients treated with empagliflozin had a significantly lower rate of CV death (3.7% versus 5.9%), all-cause death (5.7% versus 8.3%), and hospitalisation for heart failure (HHF) (5.7% versus 8.5%) compared to those treated with placebo (p<0.001). These results support the rationale to optimise antihyperglycaemic therapy with empagliflozin in addition to first-line antihyperglycaemic therapy (e.g., metformin) in order to decrease the CV risk of patients with established CVD.
Liraglutide was the next agent to demonstrate positive CV outcomes in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. 10 The LEADER trial included 9,340 patients with T2D who were at least 50 years of age with established CVD or greater than 60 years of age with major CVD risk factors. Major CVD risk factors included: microalbuminuria or proteinuria, hypertension (HTN) and left ventricular hypertrophy (LVH), left ventricular systolic or diastolic dysfunction, or an ankle-brachial index (ABI) of <0.9. At baseline, enrolled patients had a mean age of 64 years, A1C of 8.7%, and duration of diabetes of 13 years. Nearly all patients (81%) had established CVD with prior MI and prior revascularisation being the most common diagnoses. Patients were randomised to receive 1.8 mg of liraglutide or placebo once daily as a subcutaneous injection. The primary composite MACE was the same as EMPA-REG OUTCOME included CV death, nonfatal MI or nonfatal stroke.
The study resulted in a significantly lower frequency of the composite outcome in the liraglutide-treated patients versus placebo. The primary CV composite outcome occurred in 13.0% and 14.9% of the liraglutide and placebo treated patients, respectively, over a median of 3.8 years (p=0.01).
This results in a NNT of 67 patients with T2D and CVD or CVD risk factors over 3 years to prevent one additional major CV event. There was no difference between the rates of nonfatal MI, nonfatal stroke, or HHF between groups.
Patients in the liraglutide group had statistically significantly lower rates of CV death (4.7% versus 6.0%; p=0.007) and all-cause death (8.2% versus 9.6%; p=0.02) compared to those receiving placebo. While there was a nonsignificant higher rate of pancreatitis in the placebo group compared to the liraglutide group (23 versus 18; p=0.44), there was a signal toward increased risk of pancreatic cancer in the liraglutide-treated patients. There were 13 patients in the liraglutide group and five patients in the placebo group who developed a pancreatic carcinoma during the trial (p=0.06). All 18 patients with pancreatic cancer passed away and it was discovered that another four patients in the placebo group (of a total of nine) passed away from 'malignancy related to pancreatic cancer'. The study authors concluded that due to small number of cases of pancreatic cancer, the association between liraglutide and pancreatic cancer risk in this study cohort could not be confirmed or excluded. In summary, these study results support the rationale to optimise antihyperglycaemic therapy with liraglutide in addition to first-line antihyperglycaemic therapy (e.g. metformin) in order to decrease the CV risk of patients aged 60 or greater with established CVD or patients 50 years of age or older with known CV risk factors.
Semaglutide was the third of these four antihyperglycaemic agents to demonstrate positive CV outcomes in the Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6). 11 The SUSTAIN-6 trial included 2,735 patients with T2D who were at least 50 years of age, with established CVD, HF or chronic kidney disease (CKD) stage 3 to 5, or who were 60 years of age 
HR=1.97; 95% CI, 1.41 to 2.75). This corresponds to a number needed to harm (NNH) of 277 patients over 3 years to see one additional amputation.
Most affected patients (71%) had a toe or metatarsal amputation and risk of amputation was highest among those with a history of amputation or concomitant peripheral vascular disease (PVD). Study authors acknowledge that the increased risk of amputation is a new finding and caution should be exercised when using canagliflozin in patients at risk for amputation. The US prescribing information for canagliflozin has been updated to include a new black box warning regarding the risk of amputation. Overall, these study findings support the rationale to optimise antihyperglycaemic therapy with canagliflozin in addition to first line antihyperglycaemic therapy (e.g. metformin) in order to decrease the CV risk of patients at high risk for or with established CVD. Healthcare providers should screen patients for risk factors for amputation (e.g., PVD) prior to prescribing canagliflozin. Patients and healthcare providers will need to weigh the CV benefit against the risk of amputation when considering canagliflozin for the treatment of T2D.
In addition to these individual drug studies, the Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL) trial was a large, real-world study that retrospectively evaluated the risk for HHF, all-cause mortality, and the combined endpoint of HHF or all-cause mortality in patients with T2D (with and without CVD) who were new users of an approved SGLT2 inhibitor (canagliflozin, dapagliflozin and empagliflozin) compared to patients with T2D who were new users of any other antihyperglycaemic agent. 13 Safety outcomes were not assessed. Data was collected via medical claims, primary care or hospital records, and national registries for nearly 310,000 patients with T2D across six countries. Patients newly initiated on an SGLT2 inhibitor were propensity score-matched with patients newly initiated on any other antihyperglycaemic agent (including fixed-dose combinations).
After matching, the mean age was 57 years and 13% had CVD. Baseline A1C was not reported. Most new users of SGLT2 inhibitors received either canagliflozin (51%) or dapagliflozin (46%). Insulin was the most common index antihyperglycaemic agent (34%) for patients not on an
SGLT2 inhibitor, followed by dipeptidyl peptidase-4 (DPP-4) inhibitors (18%). Data analysis demonstrated that SGLT2 inhibitors reduce risk of
HHF by 39% and all-cause mortality by 51%. The study authors concluded that these data confirmed the positive outcomes demonstrate in EMPA-REG OUTCOME and further support that CV benefit may be a class effect with SGLT2 inhibitors.
Ongoing or unpublished cardiovascular outcome studies
In addition to EMPA-REG OUTCOME, LEADER, SUSTAIN-6 and the CANVAS programme, multiple other studies evaluating the CV outcomes of individual antihyperglycaemic agents or classes of agents are currently ongoing or recently completed but not yet published (see Table 2 ). positive CV outcomes data for canagliflozin will be incorporated into updated guidelines and, ultimately, into practice given the increased risk of amputations and new black box warning related to this.
The mechanism(s) behind the CV benefit of empagliflozin, liraglutide, semaglutide and canagliflozin have not been clearly established.
All four drugs have multiple beneficial effects on the body, such as glucose lowering, blood pressure (BP) lowering, and weight loss. It has been hypothesised that improvements in glycaemic control, BP and weight are linked with positive CV outcomes. However, the effects of empagliflozin, liraglutide, semaglutide and canagliflozin on these parameters in their respective CV outcomes trials were relatively modest. Across the three CV outcomes trials for the four drugs, A1C was reduced 0.24% to 0.7%, systolic BP was reduced 1 to 4 mmHg, and weight was reduced 2 to 4 kg compared with placebo. [9] [10] [11] While reduction in each surrogate marker is beneficial to the patient, the small magnitude of change does not explain the CV benefit. [28] [29] [30] The beneficial CV effects of empagliflozin are possibly related to in the body's use of ketones as a fuel source. 31 Empagliflozin may improve cardiac contractility and efficiency via preferential use of ketone bodies that produce energy more efficiently than glucose or free fatty acids. 31 Because canagliflozin has the same mechanism of action as empagliflozin, this hypothesis is likely true for canagliflozin as well.
The beneficial effects of liraglutide and semaglutide are possibly related to atherosclerosis prevention, though the definitive mechanism by which this occurs is unclear. 10, 28, 32 Until more data are available, it is unknown whether the beneficial CV effects of these drugs represent a class effect (for SGLT-2 inhibitors and GLP-1 receptor agonists) or if the CV benefit is unique to the individual agents. Another unknown is whether these CV benefits extend to a lower CV risk population, such as primary prevention patients.
Caution must be exercised to not extrapolate the results of EMPA-REG OUTCOME, LEADER, SUSTAIN-6 and the CANVAS programme to all patients with T2D. However, both SGLT-2 inhibitors and GLP-1 receptor agonists are guideline-supported add-on therapies irrespective of a patient's CV risk. 26 
Conclusion
Canagliflozin, empagliflozin, liraglutide and semaglutide have all demonstrated CV benefit in patients with T2D and existing CVD and/or high risk of CVD. Given the risk of amputation, canagliflozin is the least preferred agent of the four despite its positive CV benefit. Preference should be given to the use of empagliflozin, liraglutide and semaglutide as add-on to first-line therapy in patients with T2D and CVD or at high CVD risk who require additional medication for glucose lowering. Caution should be exercised regarding potential adverse effects; not every patient is a candidate for these hyperglycaemic agents. Multiple other CV outcomes studies are underway and will provide more insights into additional agents that also have favourable CV effects, mechanisms of CV benefit, whether CV benefits are a class effect and whether lower-risk patients derive CV benefit from these agents. ❑
